Tisagenlecleucel

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.

Historically, Jae H. Park, MD, has not paid much attention to his patients’ weight loss.

SAN DIEGO — A bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia, findings presented at ASH Annual Meeting and Exposition showed.

A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.

Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.

September is Childhood Cancer Awareness Month.

Children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia increasingly receive tisagenlecleucel in earlier settings when they have lower disease burden, according to findings presented at ASCO Annual Meeting.

An FDA mandate that requires patients who receive chimeric antigen receptor T-cell therapy to stay within a certain radius of their treatment facility for nearly a month for adverse event monitoring may be overly restrictive.

The next evolution of gene therapies may involve pitting T cells with different modifications against one another in a “race” inside a human to determine which edits produce the best results against a tumor, an expert panel predicted.

The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.